The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors

Inclusion criteria： Patients with at least one measurable lesion per RECIST (v1.1); Patients with medium or high expression of Claudin18.2 in tumor tissue samples tested by immunohistochemistry in central laboratory were included; Patients with untreated, unresectable advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with negative HER-2 immunohistochemistry or FISH test (HER-2 immunohistochemistry 0/1+ confirmed by a qualified local or central laboratory, or 2+ confirmed negative by FISH test) were included; Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 at screening and no deterioration occurs within two weeks before enrollment; Life expectancy period ≥ 12 weeks; Patients who have sufficient baseline organ function. Exclusion Criteria: Receive anti-tumor treatment within 4 weeks before the first administration or within 5 half-lives of the treatment drug, whichever is shorter; Patients who have previously used Claudin 18.2 products for treatment; With uncontrolled diseases; Who are allergic to the study drug or any of its components; Patients with a history of other primary malignant tumors at the time of screening, except for cured skin Basal-cell carcinoma or Cutaneous squamous-cell carcinoma or cervical Carcinoma in situ.